Insightec announced that its incision-free brain “surgery” technology — called Exablate 4000 (Exablate Neuro) — has been approved in China to treat essential tremor and tremors caused by Parkinson’s disease. The market approval from China’s regulatory agency for medicines and medical devices, the National Medical Products Administration, will allow the…
YTX-7739, a potential disease-modifying therapy for Parkinson’s disease, was safe, well-tolerated, and found to have a favorable pharmacological profile when given to a group of healthy volunteers. Yumanity Therapeutics provided those early findings from a recently completed single ascending-dose (SAD) Phase 1 clinical trial. Based on the results, Yumanity…
Alterity Therapeutics has been awarded a grant from the Michael J. Fox Foundation (MJFF) for animal studies to determine the optimal dose its of lead candidate ATH434, an essential step to opening trials in people with Parkinson’s disease. “I look forward to seeing the results from the…
To encourage more diversity in Parkinson’s investigations and better capture how the disorder affects patients across racial, socioeconomic, and other lines, The Michael J. Fox Foundation (MJFF) has opened an international program to fund projects that promote greater inclusion in Parkinson’s research. Awarded projects could receive from $50,000 up to…
A free virtual symposium about U.S. veterans, their families, and Parkinson’s disease (PD) is on tap for Saturday, March 20. Called “Veterans and Parkinson’s Disease: What You Need to Know,” the three-hour Zoom event runs opens at 9 a.m. EST, and is presented by the Parkinson’s Foundation and the…
Machine-learning analysis of video recordings of people thought to have Parkinson’s disease as they performed specific motor tasks was able to distinguish these suspected cases from healthy people, as well as Parkinson’s patients from those with essential tremor, a pilot study confirmed. This non-invasive,…
The Imperial College Investment Fund (ICIF) has invested £205,000 (about $283,000) in Charco Neurotech to support the development of CUE1, a non-invasive wearable device that uses controlled vibration to ease stiffness and slowness of movement in people with Parkinson’s disease. According to Lucy Jung, former student at…
A re-examination of blood samples from people with early Parkinson’s disease in a Phase 3 trial — in which Dynacirc, a blood pressure medication, failed to slow disease progression — found that those with higher blood levels of Dynacirc were slower to start an antiparkinson therapy and needed lower doses once…
The first Parkinson’s disease patient has been implanted with Newronika‘s AlphaDBS, an innovative deep brain stimulation (DBS) system, in a clinical trial conducted in Italy and Poland. DBS is an established treatment for people with Parkinson’s disease who do not respond adequately to medication. It is a surgical procedure…
Q-State Biosciences has developed a set of optimized antisense oligonucleotides (ASOs) that may serve as potential therapies for Parkinson’s disease patients with specific mutations, the company announced. These ASO candidates are designed for patients carrying mutations in the GBA gene, a key genetic risk factor for the disease’s development. Their…
Get regular updates to your inbox.
